Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olink proteomics biomarker study of PD-1 antibody plus chemotherapy in first-line advanced gastric cancer
ChiCTR2300078000Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of PD-1 Monoclonal Antibody in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Normalized protein expression. Started Dec 2023; status: recruiting.
02
Drugs
PD-1 Monoclonal Antibody
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300078000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078000.